Xortx submits a new patent for the treatment of chronic kidney disease

Calgary, alberta, jan. 03, 2024 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease (“ckd”). this patent is designed to protect new discoveries and strategies for the treatment of individuals with varied degrees of kidney function in the setting of ckd. importantly, this patent entitled “oral and sublingual formulations of xanthine oxidase inhibitors and methods of treating disease” outlines new formulations and methods for safer and more effective the use of xanthine oxidase inhibitors (xoi) in the setting of ckd in particular autosomal dominant polycystic kidney disease (adpkd), diabetic nephropathy (dn), iga nephropathy, lupus nephritis and focal segmental glomerulosclerosis.
XRTX Ratings Summary
XRTX Quant Ranking